evipedia.ai
← Back

Delphinidins for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Delphinidin, Delphinidin Chloride, Myrtillin, Delphinidin-3-glucoside, Delphinidin-3-rutinoside, Delphinidin-3,5-diglucoside, Tulipanin, Delphinidin Glycosides, Delphinol, MaquiBright

Motivation

Delphinidins are the deep blue-purple pigments that color bilberries, blackcurrants, eggplant skin, dark grapes, pomegranate, and the Chilean maqui berry. They sit within the wider family of water-soluble plant colors found across fruits and vegetables, and they carry more oxygen-hydrogen groups on their outer ring than their relatives do, which makes them the strongest free-radical scavengers of that family in laboratory tests. Concentrated berry extracts standardized for delphinidin content are now sold as capsules.

Attention grew after Chilean and Japanese research groups reported that concentrated maqui extracts blunted the rise in blood sugar following a meal and increased tear production in people with dry, tired eyes. Separately, large diet surveys have repeatedly found that people eating more of these pigments have lower rates of heart and blood-sugar disease, although surveys of eating habits cannot by themselves show that one causes the other.

This review examines what is established about delphinidins: how much reaches the bloodstream and how quickly it leaves, which effects survive controlled human testing and which rest on cell and animal work, what doses and forms have been used, what could go wrong, and how far the evidence is shaped by who funded it.

Benefits - Risks - Protocol - Conclusion

High-level orientations to delphinidins and to the pigment class they belong to, chosen for depth rather than for reaching a target count.

Only two of the six priority platforms carried qualifying content: foundmyfitness.com returns no results for delphinidin, while hubermanlab.com, chriskresser.com, and lifespan.io mention these pigments only in passing inside broader articles. Those passing mentions were left out rather than padding the list; three peer-reviewed narrative reviews on delphinidin itself complete the five.

Grokipedia

Delphinidin

Covers the named glycoside forms — myrtillin, delphinidin-3-rutinoside, delphinidin-3,5-diglucoside — alongside biosynthesis and food sources, useful for decoding the labels on standardized extracts.

Examine

No Examine article on delphinidins exists. The site’s search for “delphinidin” returns no results of any kind, so there is no dedicated supplement page, health-topic page, or article to link.

ConsumerLab

No ConsumerLab article on delphinidins exists. The term appears only inside member-only reports on other subjects, such as the bilberry supplement review, so there is no dedicated page for the compound to link.

Systematic Reviews

Pooled evidence bearing on delphinidins, drawn from randomized controlled trials (RCTs — studies that assign participants at random to the compound or to a dummy product), from meta-analyses (statistical pooling of results across studies), and, where human data are absent, from one synthesis of laboratory cell work.

The principal trade-off here is between a claimed cardiometabolic and ocular benefit and an increased tendency to bleed. Both sides are represented above: the first three papers cover the claimed effects, the Tamer review covers the platelet risk. No systematic review or meta-analysis exists on the long-term safety of concentrated delphinidin extracts, and that side of the ledger is therefore unrepresented in the pooled literature.

Mechanism of Action

Delphinidin is an anthocyanidin — the sugar-free core of the plant pigments called anthocyanins. Three hydroxyl (oxygen-hydrogen) groups on its outer ring, one more than cyanidin, make it the most reactive electron donor of the group.

In the gut, delphinidin blocks the sodium-glucose co-transporter SGLT1 (the pump that pulls glucose from food across the intestinal wall), and delphinidin-3-rutinoside triggers release of GLP-1 (glucagon-like peptide-1, the gut hormone that prompts insulin and slows stomach emptying). In blood vessels, it raises nitric oxide, relaxing the vessel wall. In cells, it activates Nrf2 (the switch that turns on the body’s own antioxidant enzymes) and dampens NF-κB (the master switch for inflammatory genes); in brain tissue it engages AMPK and SIRT1 (energy- and repair-sensing proteins).

Pharmacologically it is short-lived, poorly absorbed, and non-selective: under 1% of an oral dose reaches plasma intact, peak levels arrive about an hour after intake, and concentrations return to baseline within eight hours. No single high-affinity receptor is involved; it acts across the targets above. Distribution is mostly to gut wall, liver, and plasma, with only traces reaching brain and eye tissue. Clearance is by conjugation in the gut wall and liver and by gut-bacterial breakdown to protocatechuic and gallic acid, not by cytochrome P450 (the liver’s main drug-metabolizing enzyme family).

Mechanistic accounts compete. Because plasma levels stay far below those used in cell work, direct antioxidant scavenging is hard to sustain as the explanation; the rival account credits low-dose signaling and the longer-lived bacterial breakdown products instead.

Historical Context & Evolution

Delphinidin was named for the larkspur genus Delphinium during the era in which Richard Willstätter’s laboratory resolved anthocyanin structures, work recognized with the 1915 Nobel Prize in Chemistry. The original interest was purely a dye and food-color interest: these pigments were studied to explain and reproduce flower and fruit color, not to treat anything.

The therapeutic turn came through the eye. Delphinidin-rich bilberry preparations acquired a reputation for improving night vision after wartime reports attributed better dusk flying to bilberry jam, and European anthocyanoside products were marketed on that basis for decades. When those claims were tested, a placebo-controlled review by Canter and Ernst found eight of twelve trials reporting positive night-vision effects, but the four most recent and most rigorous randomized trials were all negative — a split the authors tied to methodology, dose, and extracts from different growing regions. The question is unresolved rather than closed: no rigorous trial has tested people with impaired night vision, and none used today’s standardized delphinidin extracts.

A second turn came from Chile, where the Mapuche have long eaten maqui berries. Once maqui was identified as the richest known delphinidin source, extracts standardized to delphinidin content were developed and tested in the 2010s for glucose control and tear production.

That period overlapped with, and outlasted, the antioxidant-capacity enthusiasm of the 1990s and 2000s; the United States Department of Agriculture withdrew its antioxidant-capacity food database in 2012, and delphinidin research shifted from scavenging power toward specific transporters and signaling proteins.

Expected Benefits

High 🟩 🟩 🟩

Endothelial Function & Arterial Stiffness

Delphinidin-type anthocyanins improve how well arteries widen in response to blood flow — measured as flow-mediated dilation (FMD, an ultrasound test of artery responsiveness) — and reduce pulse wave velocity, a measure of arterial stiffness. The proposed mechanism is increased nitric oxide availability in the vessel lining. The evidence is a 2026 systematic review and meta-analysis of 65 randomized trials in healthy participants that reported a separate delphinidin stratum, with the acute artery effect graded strong and the chronic effect moderate. Blood pressure itself was unchanged.

Magnitude: In Avendano et al., 2026, delphinidin raised flow-mediated dilation by 1.69 percentage points acutely (95% CI — the range containing the true effect — 1.20 to 2.18) and 1.59 points with sustained intake, and lowered pulse wave velocity by 0.33 units (95% CI 0.05 to 0.62).

Blood Lipid Profile ⚠️ Conflicted

Delphinidin-based products lower triglycerides and low-density lipoprotein cholesterol (LDL-C, the cholesterol fraction that drives artery plaque) and raise high-density lipoprotein cholesterol (HDL-C). Two independent meta-analyses that stratified by pigment structure both found the delphinidin stratum outperforming the cyanidin and malvidin strata, which is the strongest available argument that the structural distinction matters clinically rather than only chemically. Against this, a crossover trial of isolated bilberry anthocyanins found no LDL-C change. The effect sizes are modest and would not replace lipid-lowering therapy for anyone with an established indication for it.

Magnitude: Araki et al., 2021 reported mean differences of −0.24 mmol/L for triglycerides, −0.28 mmol/L for LDL-C, and +0.11 mmol/L for HDL-C for delphinidin-based anthocyanins, with no significant change for cyanidin- or malvidin-based ones; Avendano et al., 2026 found −0.10 mmol/L for triglycerides.

Medium 🟩 🟩

Postprandial Glucose Control ⚠️ Conflicted

Standardized maqui extracts blunt the blood-sugar rise after a meal, attributed to intestinal SGLT1 blockade plus GLP-1 release. The evidence conflicts by timescale: acute dosing effects are consistent across trials, while sustained dosing gives modest and inconsistent results, and one structure-stratified meta-analysis could not confirm a significant glucose-metabolism effect for any pigment type even as lipids improved. Most of this work was funded by the extract manufacturers, MNL-Chile and Anklam Extrakt, whose commercial interest lies in a positive result.

Magnitude: In an open-label three-month trial of 31 people with mild prediabetes, Alvarado et al., 2016 reported HbA1c (glycated hemoglobin, average blood sugar over about three months) falling from 5.65% to 5.35%; Hidalgo et al., 2014 found significantly lower post-meal glucose and insulin versus placebo in ten glucose-intolerant volunteers.

Dry Eye Relief & Tear Production

Delphinidin-rich maqui extract increases tear volume and reduces dry-eye symptom scores, proposed to work by limiting oxidative damage to the lacrimal (tear-producing) glands and reducing inflammatory signaling at the eye surface. Three human trials agree in direction, including one independent placebo-controlled trial that also documented falling inflammatory messengers in tear fluid. All are small and short, which is why the grade is not higher; a 2026 systematic review nonetheless named this the single most consistent maqui finding.

Magnitude: Yamashita et al., 2019 found tear production 6.4 ± 8.1 mm higher on Schirmer’s test after four weeks at 60 mg versus placebo (n = 74); Hitoe et al., 2014 reported symptom scores falling from 40.2 to 11.1 out of 60 over 60 days at the same dose.

Systemic Oxidative Stress Reduction

Delphinidin-rich extract lowers circulating markers of oxidative damage — oxidized LDL and F2-isoprostanes, both fingerprints of fat molecules attacked by free radicals — in overweight adults and smokers. Mechanistically this is attributed more to Nrf2-driven upregulation of the body’s own antioxidant enzymes than to direct scavenging, given how little compound reaches plasma. Notably the markers returned toward baseline 40 days after stopping, and blood pressure, weight, and lipids did not move in the same trial.

Magnitude: Davinelli et al., 2015 found significant reductions in plasma oxidized LDL and urinary F2-isoprostanes after four weeks at 162 mg anthocyanins daily in 42 adults, with the difference gone by the 40-day follow-up.

Low 🟩

Cognitive & Neuroprotective Effects

Delphinidin reduced brain plaques and memory loss in an Alzheimer’s mouse model by preventing senescence in microglia, the brain’s resident immune cells, acting through AMPK and SIRT1; a separate mouse model showed reduced neuroinflammation and movement deficits in Parkinson’s disease. No human trial has tested delphinidin specifically for cognition.

Magnitude: Direction is consistently favorable in rodent models of Alzheimer’s and Parkinson’s disease at doses far above dietary exposure (Liu et al., 2025; Grotemeyer et al., 2026); the literature reports no human outcome figure for delphinidin on cognition.

Skeletal Muscle Preservation

Delphinidin limited muscle wasting during disuse in rodents and shifted muscle fibers toward the fatigue-resistant slow type in cultured muscle cells, again through AMPK. The relevance to age-related muscle loss in people is untested.

Magnitude: Direction is protective against atrophy under disuse and immobilization conditions in rodent and cell models (Murata et al., 2017); the literature reports no human outcome figure.

Uric Acid Lowering

Delphinidin-3-glucoside binds the flavin site of xanthine oxidase (the enzyme that makes uric acid), lowering urate in preclinical models. This is a plausible but unconfirmed route to reduced gout risk.

Magnitude: Urate falls in the direction expected from enzyme inhibition, demonstrated in binding and animal work on red kidney bean delphinidin-3-glucoside (Chen et al., 2026); the literature reports no human outcome figure.

Bone Loss Prevention

Delphinidin and delphinidin-enriched maqui extract suppress osteoclasts (the cells that break down bone), preventing bone loss in mouse models of osteoporosis. The mechanism is inhibition of excessive osteoclast formation, but no controlled human trial has tested delphinidin on bone density.

Magnitude: Direction is reduced bone breakdown and protection against bone loss in mouse models of osteoporosis (Moriwaki et al., 2014; Nagaoka et al., 2019); the literature reports no human outcome figure.

Speculative 🟨

Cancer Progression & Metastasis Suppression

Delphinidin suppresses growth and spread across many cancer cell lines and tumors grown in mice. No controlled human study exists; the basis is entirely preclinical, at concentrations human blood cannot reach (Sharma et al., 2021).

Retinal Photoreceptor Protection

Maqui extract and delphinidin-3,5-diglucoside prevented light-induced photoreceptor cell death in culture, a retinal target distinct from the tear gland. No human retinal study exists; the basis is mechanistic only (Tanaka et al., 2013).

Benefit-Modifying Factors

  • Gut microbiome composition: Most circulating activity comes from bacterial breakdown products, so the species present determine how much protocatechuic and gallic acid a given dose yields. This is the largest single source of between-person variability.

  • Conjugation enzyme variants: Common polymorphisms in COMT (the enzyme that attaches methyl groups) and the UGT1A family (which attach sugar-acid groups) alter how fast delphinidin metabolites are cleared, plausibly shifting exposure severalfold between individuals.

  • Baseline biomarker levels: Lipid and glucose effects concentrate in those starting outside optimal range. Trials in prediabetes moved HbA1c; trials in healthy adults with normal lipids found no change. Better baselines predict smaller returns.

  • Sex-based differences: Cohort associations for anthocyanin intake and cardiovascular risk are generally stronger in women, partly reflecting higher berry intake. No human delphinidin trial has been powered to test a sex interaction directly.

  • Pre-existing health conditions: Prediabetes, dry eye disease, and elevated LDL-C are the states in which benefit has been demonstrated. Established type 2 diabetes on multiple agents and normal tear function are not.

  • Age-related considerations: Older adults have thinner tear films and stiffer arteries, so the ocular and pulse-wave endpoints have more room to move. Against this, absorption of polyphenols declines modestly with reduced gastric acid output.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Poor Oral Bioavailability & Rapid Clearance

The dominant practical risk is that a dose does nothing. Intact delphinidin glycosides are absorbed at well under 1% and cleared within hours, so plasma concentrations sit orders of magnitude below those used in the cell work that generates most benefit claims. Human pharmacokinetic measurement confirms this directly. The consequence is a wide gap between preclinical promise and demonstrable human effect, and it is the single best explanation for the inconsistency across chronic-dosing trials.

Magnitude: In 12 healthy adults, Schön et al., 2018 measured peak plasma delphinidin-3-glucoside at 1.0 ± 0.3 hours after a single dose of standardized maqui extract, with concentrations returning nearly to baseline within 8 hours.

Medium 🟥 🟥

Additive Glucose Lowering with Diabetes Medication

Blocking intestinal SGLT1 and prompting GLP-1 release reduces post-meal and fasting glucose. Stacked on insulin, sulfonylureas, or meglitinides (two classes of oral drug that push the pancreas to release more insulin), that adds a second glucose-lowering mechanism the prescriber has not accounted for, and hypoglycemia is the foreseeable consequence. No hypoglycemic event has been reported in a published trial, but every trial excluded people on glucose-lowering drugs, so the absence of reports is not evidence of absence.

Magnitude: Fasting and post-meal glucose and insulin both fell dose-dependently in prediabetic volunteers given standardized extract before a glucose load (Alvarado et al., 2016); the literature reports no figure for the additive effect with medication because no such study exists.

Platelet Inhibition & Bleeding Potential

Delphinidin-3-glucoside inhibits platelet activation and reduces thrombus formation in animal models, and a systematic review of platelet-active plant compounds places anthocyanidins among the agents with measurable signaling effects. In someone on an anticoagulant or antiplatelet drug (medicines that thin the blood or stop platelets clumping), or facing surgery, this shifts an intended benefit into a bleeding hazard. Severity is dose- and context-dependent and reverses on stopping, given the short half-life.

Magnitude: Yang et al., 2012 reported dose-dependent inhibition of platelet activation and reduced thrombus growth in mice; no human bleeding-outcome figure exists, because no bleeding endpoint has been measured in a delphinidin trial.

Low 🟥

Gastrointestinal Discomfort at High Doses

Concentrated anthocyanin extracts occasionally produce nausea, loose stools, or abdominal cramping, most plausibly from unabsorbed pigment reaching the colon and being fermented. Controlled trials of anthocyanin-rich extract report tolerability comparable to placebo, so this sits at nuisance level and resolves on dose reduction.

Magnitude: Gastrointestinal complaints occurred at rates not distinguishable from placebo in a randomized trial of anthocyanin-rich extract (Biedermann et al., 2024); no controlled trial has quantified an incidence rate specific to delphinidin extracts.

Reduced Non-Heme Iron Absorption

Polyphenols bind iron in the gut and reduce absorption of the plant-derived (non-heme) form. Delphinidin has not been singled out, but the class effect is well documented and matters for menstruating women, frequent blood donors, and vegetarians taking extract with meals.

Magnitude: Direction is a reduction in non-heme iron uptake, strongest when polyphenol and iron are consumed in the same meal (Milman, 2020); no figure exists for delphinidin specifically, only for polyphenol classes as a whole.

Speculative 🟨

Suppression of Angiogenesis-Dependent Repair

Delphinidin blocks vascular endothelial growth factor signaling, which drives new blood-vessel growth. The theoretical concern is impaired wound healing after injury. Basis: cell and tumor-model work only, no clinical report (Keravis et al., 2015).

Drug-Metabolizing Enzyme Interference

Anthocyanins inhibit CYP3A4 (the enzyme that clears many prescription drugs) in cell assays. Potency is weak and no clinical interaction has been reported; the basis is in vitro reports only (Dreiseitel et al., 2008).

Risk-Modifying Factors

  • Conjugation enzyme variants: Slow UGT1A and COMT variants prolong metabolite exposure, theoretically amplifying platelet and enzyme-inhibition effects. No pharmacogenetic study has tested this for delphinidin; the inference is from polyphenol handling generally.

  • Baseline biomarker levels: Low baseline ferritin makes the iron-absorption effect consequential rather than academic. Low platelet count or an unstable clotting-time reading makes the antiplatelet effect consequential rather than academic.

  • Sex-based differences: Menstruating women carry higher baseline risk from the iron-absorption effect. No sex difference in bleeding or glycemic adverse events has been demonstrated, as no trial has been powered to detect one.

  • Pre-existing health conditions: Bleeding disorders, peptic ulcer disease, planned surgery, and drug-treated diabetes convert the mechanistic concerns above into real ones. Existing dry eye or prediabetes does not add risk.

  • Age-related considerations: Older adults more often take anticoagulants and antiplatelet drugs and more often have reduced kidney function, so both the bleeding and the additive-glucose concerns concentrate at the upper end of the target range.

Key Interactions & Contraindications

  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): Caution. Additive bleeding risk from platelet inhibition. Mitigation: clotting-time stability is checked two weeks after starting or stopping, and the extract is held before invasive procedures.

  • Antiplatelet drugs (clopidogrel, ticagrelor, prasugrel, low-dose aspirin): Caution. Additive suppression of platelet activation, with bruising and prolonged bleeding the clinical consequence. Mitigation: combination with dual antiplatelet therapy after stent placement is unsupported.

  • Insulin and insulin secretagogues, drugs prompting insulin release (glipizide, glyburide, repaglinide): Caution. Additive glucose lowering risking hypoglycemia, especially when taken before meals. Mitigation: capillary glucose is monitored for the first two weeks, with the prescriber involved in dose adjustment.

  • SGLT2 (a kidney glucose transporter) inhibitors and alpha-glucosidase (a starch-digesting gut enzyme) inhibitors (empagliflozin, dapagliflozin, acarbose): Monitor. Overlapping mechanisms on glucose handling and absorption; the clinical consequence is unpredictable post-meal glucose rather than a defined hazard.

  • Over-the-counter analgesics (ibuprofen, naproxen, aspirin): Caution. Additive bleeding risk, with gastrointestinal bleeding the consequence of concern. Mitigation: use is separated in time, and sustained combination carries the greatest hazard in anyone with ulcer history.

  • Oral iron supplements (ferrous sulfate, ferrous bisglycinate): Monitor. Polyphenol binding reduces iron uptake. Mitigation: the extract and the iron dose are separated by at least two hours.

  • Antiplatelet supplements (fish oil, ginkgo, garlic extract, nattokinase, high-dose vitamin E): Caution. Additive platelet inhibition, the clinical consequence being bruising and prolonged bleeding time. Mitigation: one platelet-active supplement at a time keeps the effect attributable.

  • Glucose-lowering supplements (berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract): Caution. Additive post-meal glucose lowering; hypoglycemia is possible in anyone also on medication. Mitigation: staggered introduction keeps a single variable changing at a time.

  • Other interventions: Monitor. Time-restricted eating, ketogenic diets, and prolonged fasting already lower post-meal glucose, so the extract’s glycemic contribution becomes redundant or additive depending on timing.

Populations who should avoid Delphinidins:

  • Anyone on warfarin with an unstable or supratherapeutic clotting-time reading above 3.0
  • Anyone within 14 days of scheduled surgery or an invasive procedure
  • Anyone with a platelet count below 50 × 10⁹/L or a diagnosed bleeding disorder such as hemophilia or von Willebrand disease
  • Anyone on insulin or a sulfonylurea with hypoglycemia unawareness or an HbA1c already below 6.5%
  • Pregnant or breastfeeding women, on absence of safety data rather than evidence of harm
  • Children under 18, for the same reason

Risk Mitigation Strategies

  • Discontinuation 14 days before surgery: Stopping the extract two weeks before any invasive procedure removes the additive antiplatelet effect well beyond the compound’s few-hour clearance, mitigating perioperative bleeding.

  • Clotting stability checks on anticoagulants: For anyone on warfarin, the clotting-time reading is taken at baseline, at two weeks, and at four weeks after starting, and held within the prescribed 2.0–3.0 band to catch additive bleeding risk.

  • Capillary glucose check on diabetes medication: Testing fasting and two-hour post-meal glucose daily for the first 14 days catches additive hypoglycemia from stacked SGLT1 blockade before it becomes symptomatic.

  • Two-hour separation from iron: Taking the extract at least two hours from any iron supplement or iron-rich meal prevents the polyphenol-iron binding that reduces non-heme iron absorption.

  • Lower studied dose first: Beginning at 30–60 mg of standardized extract daily and holding for two weeks before escalating to 180 mg limits gastrointestinal discomfort and reveals individual sensitivity early.

  • A standardized, tested product: Choosing an extract with a stated delphinidin percentage and third-party testing mitigates the risk of an inert or dye-adulterated product, the failure mode that poor bioavailability already makes likely.

Therapeutic Protocol

  • Glycaemic protocol: 180 mg of maqui extract standardized to ≥25% delphinidins once daily in the morning, or 60–180 mg taken one hour before the largest carbohydrate meal, as used in the Chilean prediabetes trials.

  • Ocular protocol: 60 mg daily of maqui extract standardized to delphinidin-3,5-diglucoside, taken continuously for at least four weeks before assessing response, as used in the Japanese dry-eye trials.

  • Whole-food alternative: 50–150 mg total anthocyanins daily from bilberries, blackcurrants, or dark grapes, the intake range at which the cohort associations and the lower-dose trial arms operate.

  • Competing approaches: The extract route and the whole-food route are both defensible. Extracts give a known delphinidin dose; whole fruit delivers fiber and a mixed pigment profile. Neither has been tested head-to-head.

  • Who popularized each: The standardized-extract approach was developed commercially by MNL-Chile and Anklam Extrakt (Delphinol) and by Oryza Oil & Fat (MaquiBright), and trialled by Vigil and Alvarado’s group at Pontificia Universidad Católica de Chile.

  • Best time of day: Morning on an empty stomach for glycemic use, since the effect is on the next meal’s absorption. Time of day is immaterial for ocular use; consistency matters more.

  • Half-life: Short. Peak plasma levels arrive about one hour after intake and return to baseline within eight hours, implying an effective half-life of roughly one to two hours for the intact glycosides.

  • Single versus split dosing: Split dosing before meals suits the glycemic indication, matching the compound’s brief window of intestinal action. A single daily dose suffices for ocular and lipid endpoints, which depend on cumulative exposure.

  • Genetic considerations: COMT and UGT1A variants alter metabolite clearance and may explain non-response; APOE4 (a gene variant raising Alzheimer’s risk) status is relevant only to the untested cognitive indication. No pharmacogenetic dosing rule has been validated.

  • Sex-based differences: No trial has established a sex-specific dose. Doses studied were identical for men and women, and observed responses have not been reported to differ by sex.

  • Age-related considerations: Doses were unchanged across the 30–65 age range studied. For adults over 70, the lower end of each range is a reasonable starting point given more frequent anticoagulant use.

  • Baseline biomarker considerations: Response scales with how far the starting HbA1c, LDL-C, or tear volume sits from optimal. Someone already optimal on all three has little to gain from either protocol.

  • Pre-existing condition considerations: Prediabetes, elevated LDL-C, and dry eye disease are the states with demonstrated response. Established type 2 diabetes on multiple drugs was excluded from every trial and is not covered by these protocols.

Discontinuation & Cycling

  • Not a lifelong commitment: Delphinidin extracts are used as long as the target endpoint justifies them. Nothing about the compound requires indefinite use, and no dependency mechanism has been described.

  • Effects wash out: Oxidative-stress markers returned toward baseline 40 days after stopping in the one controlled trial that measured follow-up, so benefits are maintenance-dependent rather than durable.

  • No withdrawal effects: No withdrawal syndrome, rebound, or discontinuation effect has been reported in any human trial. The short half-life makes a physiological rebound implausible.

  • No taper needed: Abrupt discontinuation is what every trial did at study end without incident. The only reason to taper would be to observe which effects fade, not to avoid harm.

  • Cycling not supported: All human trials used continuous daily dosing for four weeks to three months. No tolerance has been documented, so there is no established rationale for cycling on and off.

Sourcing and Quality

  • Delphinidin standardization: A label stating total anthocyanins alone is insufficient, since cyanidin- and malvidin-based products did not show the lipid effects. Trial-grade material states a delphinidin percentage, typically ≥25%.

  • Third-party testing: Independent verification by a body such as USP, NSF International, or Informed Choice is the practical check. Berry extracts are among the categories where independent testing has repeatedly found authenticity failures.

  • Adulteration is the main hazard: Bilberry and maqui extracts have been adulterated with cheaper fruit powders and synthetic dyes that mimic the color without the pigment. A certificate of analysis with chromatographic profiling is the practical defence.

  • Formulation and stability: Anthocyanins degrade with heat, light, and neutral pH. Opaque packaging, current expiry dating, and storage below 25 °C preserve content; loose powders faded from purple toward brown have already lost it.

  • Established branded extracts: Delphinol (Anklam Extrakt) and MaquiBright, also sold as BrightSight (Oryza Oil & Fat), are the two extracts on which the human trials were performed. Both manufacturers funded much of that research.

  • Whole-food sourcing: Frozen wild bilberries and blackcurrants retain anthocyanin content well and avoid the adulteration problem entirely, at the cost of an unknown delphinidin dose per serving.

Practical Considerations

  • Time to effect: Post-meal glucose effects appear within one hour of the first dose. Tear production changes take about four weeks. Lipid changes take four to twelve weeks, and oxidative-stress markers about four weeks.

  • Pitfall — unstandardized product: Buying generic maqui or açaí powder rather than a delphinidin-standardized extract is the most common mistake. Trial doses cannot be reproduced from a product with no stated pigment content.

  • Pitfall — wrong timing: Taking the extract with or after a meal forfeits most of the glycemic effect, which depends on the compound occupying intestinal glucose transporters before food arrives.

  • Pitfall — expecting the preclinical result: Most published delphinidin effects come from concentrations human blood cannot reach. Treating cancer or neurological findings as achievable through supplementation misreads what the evidence supports.

  • Regulatory status: In the United States delphinidin extracts are sold as dietary supplements under the Dietary Supplement Health and Education Act, requiring no pre-market efficacy proof. No health claim for them has been authorized by European regulators.

  • Cost and accessibility: Neither exceptional. Standardized maqui extract runs roughly 20 to 40 US dollars monthly and is widely available online, so cost is not a meaningful barrier for this audience.

Interaction with Foundational Habits

  • Sleep: No direct interaction. Delphinidin is not stimulant or sedative, and no trial has reported sleep changes in either direction. The indirect route is through dry-eye relief, which can reduce the evening screen-related eye discomfort that delays settling. Timing relative to bedtime is unconstrained.

  • Nutrition: Direct and mechanism-driven. The glycemic effect requires dosing before carbohydrate, so it potentiates a lower-glycemic diet and is largely wasted on a low-carbohydrate one. It blunts non-heme iron absorption, so a two-hour gap from iron-rich plant meals and from iron supplements preserves uptake.

  • Exercise: Indirect and mildly potentiating. Improved artery responsiveness and the fiber-type shift seen in cell work both point in the direction of endurance training rather than against it. Unlike high-dose antioxidant vitamins, no blunting of training adaptation has been demonstrated for anthocyanins at dietary doses.

  • Stress management: Indirect. Lower oxidative-stress markers and reduced inflammatory signaling overlap with what stress reduction achieves, but no trial has measured cortisol or a stress response after delphinidin. An ongoing Chilean trial pairing maqui with a prebiotic and probiotic is testing anxiety and stress hormone directly.

Monitoring Protocol & Defining Success

Baseline testing establishes whether there is anything to improve, since response scales with distance from optimal. The baseline panel covers a fasting lipid panel, fasting glucose and insulin, HbA1c, high-sensitivity C-reactive protein (hs-CRP, a marker of low-grade inflammation), and ferritin (the iron storage protein). The ocular protocol adds a baseline Schirmer’s test, which measures tear volume on a paper strip. Anticoagulant use adds a baseline clotting-time reading.

Ongoing monitoring follows the timescale of each endpoint: the clotting-time reading is repeated at 2 and 4 weeks under anticoagulation, glucose and tear measures at 4 weeks, and the full lipid, HbA1c, inflammation, and ferritin panel at 12 weeks, then every 6–12 months while use continues. Success means measurable movement in the specific marker that justified starting; no movement by 12 weeks is a reason to stop rather than to escalate.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–85 mg/dL Primary glycemic target Conventional range 70–99 mg/dL is far wider; 8–12 h fast required
HbA1c 4.9–5.4% Three-month average glucose Conventional cutoff is <5.7%; unreliable with anemia or recent blood loss
Fasting insulin ≤5 µIU/mL Tracks insulin resistance, the glycemic endpoint that moved least consistently Conventional labs report 2–25 µIU/mL as normal; pair with fasting glucose
LDL-C <100 mg/dL, <70 with established plaque The lipid fraction delphinidin moved most in structure-stratified pooling LDL-C is low-density lipoprotein cholesterol; conventional cutoff <130 mg/dL
Triglycerides <80 mg/dL Second lipid endpoint with a delphinidin-specific effect Conventional cutoff <150 mg/dL; requires a 12 h fast
HDL-C >55 mg/dL (men), >65 mg/dL (women) Third lipid endpoint, rose in the delphinidin stratum HDL-C is high-density lipoprotein cholesterol; conventional cutoffs >40 and >50 mg/dL
hs-CRP <0.5 mg/L Tracks the inflammatory signaling the compound is proposed to dampen Conventional cutoffs are far looser, <1 mg/L low risk and >3 mg/L high risk; a reading within 2 weeks of any infection or injury is invalid, so testing is deferred
Ferritin 50–100 ng/mL Catches the iron-absorption risk before it becomes anemia Conventional range extends to 400 ng/mL; rises spuriously with inflammation, so it is read beside hs-CRP
Clotting time (INR) No delphinidin-specific target; under anticoagulation the prescribed band, usually 2.0–3.0, is held, and drift from the individual’s own pre-supplement baseline is the value tracked Detects the additive antiplatelet effect INR is the international normalized ratio, a standardized clotting-time measure; relevant only on warfarin
Schirmer’s test ≥10 mm in 5 minutes Objective tear volume, the ocular success criterion Values ≤5 mm define dry eye; measurement at the same time of day matters, as tear output falls through the day

Qualitative markers matter alongside the numbers, particularly for the ocular indication where symptom burden diverges from tear volume:

  • Eye comfort through a long screen day, including burning, grittiness, and the frequency of reaching for artificial tears
  • Visual fatigue and the ease of refocusing between near and far work in the late afternoon
  • Post-meal energy stability, specifically the absence of the mid-afternoon slump that follows a glucose spike
  • Unusual bruising, gum bleeding, or nosebleeds, which are the earliest signals of the antiplatelet effect
  • Digestive comfort in the first two weeks, since gastrointestinal complaints are the most likely reason to reduce the dose

Emerging Research

  • Maqui, anxiety and inflammation: A randomized, double-blind Chilean trial pairs 1 g maqui with inulin and Bacillus coagulans in a fruit compote, testing perceived anxiety, nail cortisol, and inflammatory cytokines in 30 university students (NCT07504081).

  • Anthocyanidin metabolites and brain signaling: A University of California, Davis study in 12 healthy adults tests whether black rice extract and its anthocyanidin breakdown products alter brain-derived neurotrophic factor, probing the metabolite hypothesis directly (NCT06594848).

  • Bilberry after heart attack: The largest ongoing trial of a delphinidin-rich food, enrolling 900 participants with prior myocardial infarction or type 2 diabetes to test bilberry and oat intake, with three-month LDL cholesterol change as the primary endpoint (NCT03620266).

  • Anthocyanins for post-surgical arrhythmia: A phase 1/2 University of Michigan trial of anthocyanin-rich grape powder in 70 patients, testing prevention of atrial fibrillation after cardiac surgery — a hard endpoint rather than a surrogate (NCT05991700).

  • Evidence that could weaken the case: Aboufarrag et al., 2022 found isolated bilberry and black rice anthocyanins changed neither LDL cholesterol nor other cardiovascular markers in adults with raised cholesterol, directly contradicting the structure-stratified lipid finding.

  • The bioavailability question: Whether benefits belong to delphinidin or to its bacterial breakdown products is the pivotal open question. Kumkum et al., 2026 show active concentrations exceed circulating levels, so metabolite-focused trials could either rescue or dismantle the field.

  • Independent replication: Almost every positive maqui trial was manufacturer-funded. Kundu et al., 2023 is the notable independent replication on the ocular endpoint; further non-industry trials on glycemic endpoints would materially change confidence either way.

Conclusion

Delphinidins are the deepest-colored members of the plant pigment family that gives bilberries, blackcurrants, and the Chilean maqui berry their blue-purple hue, and their chemistry makes them the most reactive of that family. For someone already tracking their own markers and willing to act on them, two findings stand out: pooled trial data show these pigments improving how well arteries widen and modestly improving blood fats, with the delphinidin-rich products outperforming their chemical relatives, and several small trials show concentrated maqui extract increasing tear production and easing dry, tired eyes. A blunting of the blood-sugar rise after meals is real in the short term but inconsistent over months.

Against this sits an unusually clear ceiling. Very little of an oral dose reaches the bloodstream and what does is gone within hours, so most of the striking laboratory findings — on cancer cells, on brain ageing, on muscle — describe concentrations the body does not achieve from capsules. The practical concerns are additive bleeding tendency alongside blood thinners, additive blood-sugar lowering alongside diabetes drugs, and reduced iron uptake from plant foods.

The evidence base carries a visible conflict of interest: the companies selling the standardized extracts funded most of the human trials, and much of the consumer-facing writing comes from supplement retailers. One independent eye trial has reproduced its finding; the metabolic work has not yet been independently repeated, and that gap remains part of the picture.

Top - Benefits - Risks - Protocol